LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 29, 2005--NitroMed (NASDAQ:NTMD) said today that its research program with Boston Scientific (NYSE:BSX), under which NitroMed's nitric oxide-enhancing technology was being studied in connection with restenosis in balloon angioplasty, will conclude on December 31, 2005. NitroMed intends to continue to explore the use of its nitric oxide-enhancing technology in medical devices.